Levodopa/Carbidopa Teva (Carbidopa, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system it is converted to dopamine, replenishing the neurotransmitter that is deficient in Parkinsonian disorders. Carbidopa blocks peripheral conversion, allowing more levodopa to reach the brain.

The appropriate dose of Levodopa/Carbidopa is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage regimens can vary widely, and adjustments are made during follow‑up visits.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To request Levodopa/Carbidopa, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson's disease, directly replacing dopamine. Other classes such as dopamine agonists, MAO‑B inhibitors, or COMT inhibitors are often used as adjuncts or alternatives when levodopa is insufficient or causes intolerable side effects.

Levodopa/Carbidopa tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, although high‑protein meals may affect absorption. Patients are advised to follow the prescriber’s instructions regarding timing and frequency.

Serious adverse events include dyskinesia (involuntary movements), neuropsychiatric effects such as hallucinations or severe depression, and marked orthostatic hypotension. Prompt medical evaluation is required if any of these symptoms develop.

Levodopa/Carbidopa is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients. Caution is advised for individuals with narrow‑angle glaucoma, severe cardiovascular disease, or hepatic impairment, and it should be avoided in those taking non‑selective MAO inhibitors.